ArticleAnnals of surgical oncology2025
Management and Outcomes of Merkel Cell Carcinoma in Canada Between 2000 and 2018 from the Pan-Canadian Merkel Cell Collaborative.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management and survival outcomes of patients with Merkel cell carcinoma (MCC) in Canada are currently unknown. The objective of this study was to investigate the management and outcomes of patients diagnosed with MCC in Canada from 2000 to 2018. PATIENTS AND
methodsThis retrospective cohort study evaluates management and temporal survival differences among patients diagnosed with MCC in ten large urban university centers in three provinces during three periods: 2000-2005, 2006-2011, and 2012-2018.
resultsThere were 899 patients included with a median follow-up of 22.8 months. There were no significant changes in patient and tumor characteristics between the three periods. There were increases in the use of radiologic staging (2000-2005, 53.4%; 2006-2011, 73.7%; 2012-2018, 78.1%; p < 0.01), surgery as the sole treatment (2000-2005, 25.7%; 2006-2011, 34.0%; 2012-2018, 31.8%; p = 0.02), and surgery with adjuvant radiation (2000-2005, 37.2%; 2006-2011, 36.2%; 2012-2018, 43.7%; p =0.02) during the study period. Between 2000 and 2018, the 5-year median overall survival (OS) was 47.9% (95% confidence interval (CI) 43.2-55.8%), disease-free survival was (DFS) 48.9% (95% CI 42.4-55.1%), and cancer-specific survival (CSS) was 49.7% (95% CI 43.2-55.8%). There were no significant differences in OS and DFS between the three periods on multivariable analysis. Compared with 2000-2005, there was no significant difference in CSS from 2006 to 2011 (hazard ratio (HR) 1.02 95% CI 0.66-1.62, p = 0.9), but there was a significant improvement in CSS from 2012 to 2018 (HR 0.57 95% CI 0.34-0.97, p = 0.04).
conclusionsDespite changes in the utilization of staging, surgery, and radiation, the prognosis of patients with MCC in Canada remains poor, highlighting the need for improved management strategies.
Indexed as
Identifiers
40319206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.